PLUS THERAPEUTICS INC (PSTV)

US72941H5090 - Common Stock

1.8  0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
220K4.913M
2,133.18%		5.185M
5.54%
EBITDA
YoY % growth
-11.77M
-39.62%		-19.09M
-62.19%		-12.693M
33.51%		-10.2M
19.64%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
-12.17M
-38.30%		-19.71M
-61.96%		-13.321M
32.42%		-22.104M
-65.93%
Operating Margin
N/A-8,959.09%-271.14%-426.31%
EPS
YoY % growth
-1.13
29.29%		-12.60
-1,015.04%		-4.53
64.05%		-2.46
45.74%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-1.11
47.06%
Revenue
Q2Q % growth		1.721M
237.45%
EBITDA
Q2Q % growth		-2.55M
EBIT
Q2Q % growth		-5.05M
-6.98%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.84
74.55%		-1.090.2523.21%
Q3 2023
Q2Q % growth		 -1.00
64.91%		-1.140.1412.66%
Q2 2023
Q2Q % growth		 -0.59
83.61%		-1.951.3669.79%
Q1 2023
Q2Q % growth		 -2.10
26.32%		-1.94-0.16-8.36%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 1.313M
775.33%		1.084M229K21.13%
Q3 2023
Q2Q % growth		 1.24M
1,671.43%		1.319M-79K-5.99%
Q2 2023
Q2Q % growth		 1.85M
∞%		805.545K1.044M129.66%
Q1 2023
Q2Q % growth		 510K
∞%		756.503K-246.503K-32.58%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS-51.39% -106.96% -24.71% -53.18%
Revenue-0.75% -7.57% -9.35% -7.2%